Innate Immunity in Pneumonic Sepsis
Innate Immunity in Pneumonic Sepsis
批准号:
9383252
负责人:
Shanshan Cai
金额:
$37.0万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-01 至 2021-08-31
关键词:
Adaptor Signaling ProteinAddressAdoptive TransferAnti-Bacterial AgentsAnti-Inflammatory AgentsAntibiotic TherapyAttenuatedBacteriaBacterial Drug ResistanceBacterial InfectionsBacterial PneumoniaBindingCASP1 geneCellsClinicalCoculture TechniquesDeath RateDefense MechanismsDendritic CellsDiseaseEquilibriumGoalsHealth ExpendituresHost DefenseHost Defense MechanismHost resistanceHumanImmuneImmune signalingImmunityImmunotherapeutic agentImmunotherapyIn VitroInfectionInflammatoryInflammatory ResponseInjuryInnate Immune ResponseInnate Immune SystemInterleukin-1Interleukin-17Interleukin-18InterleukinsInvestigationKlebsiella pneumonia bacteriumKnockout MiceLungLymphocyteMediatingMorbidity - disease rateMulti-Drug ResistanceMusMyeloid CellsNatural ImmunityNeutrophil InfiltrationNucleotidesOrganPathway interactionsPneumoniaPopulationPrevention strategyProductionRIPK2 geneResistanceRoleSepsisSignal TransductionSystemSystemic infectionT-LymphocyteTestingTissuesToll-like receptorsVaccinesVariantWorkburden of illnesscarbapenemasechemokinecytokinedesignextracellularimprovedin vivoinnovationinterleukin-23migrationmortalityneutrophilnoveloverexpressionpathogenreceptorresponsetreatment strategy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
SUMMARY
Lung infections are a leading cause of sepsis that poses global mortality and morbidity. Effective
clearance of pathogens from the lung is dependent on successful innate immunity. Understanding the
innate defense mechanisms in the lung is crucial for improved immunotherapeutics or vaccines to reduce
this burden of disease. The signaling cascades triggering innate immunity consist of a delicate balance
between pro-inflammatory responses, and counteracting anti-inflammatory responses. It is however
poorly understood how these innate immune signaling cascades converge to provide efficient host
defense while attenuating inflammatory tissue damage. To delineate the host defense mechanisms in the
lungs and extrapulmonary organs, we have focused on a primary gram-negative extracellular pathogen,
Klebsiella pneumoniae since this bacterium induces severe pneumonia followed by sepsis; and multiple
drug-resistant and hypervirulent variants have recently emerged to cause devastating pulmonary and
systemic infections. Recognition of pathogens is the first critical step leading to neutrophil influx in the
lung. Regarding bacterial recognition, nucleotide-binding oligomerization domain (NOD)-like receptors
(NLRs) were implicated. However, the role of NLRs, such as NOD1 and NOD2 s in host defense against
K. pneumoniae remains unexplored. NOD1/2 signaling cascades involve the adaptor protein RIP2. We
now provide preliminary evidence that NOD2 is involved in host defense during K. pneumoniae infection,
which include: 1) Mice deficient in RIP2 demonstrate reduced survival, higher bacterial burden and
decreased neutrophil recruitment to the lungs and extrapulmonary organs; 2) NOD2-deficient mice show
attenuated neutrophil recruitment to the lungs; 3) NOD2-deficient mice demonstrate decreased caspase-
1 activation and interleukin (IL)-1productionin the lung; 4) Both IL-1 and IL-18 are important for host
resistance against K. pneumoniae and 5) RIP2 regulates IL-23 and IL-17 production in the lungs. These
findings collectively support the hypothesis that the initial interaction of K. pneumoniae with the lung
cells leads to NOD2 activation followed by IL-1and IL-18 production which then induces IL-17A-
mediated neutrophil-dependent immunity in the host. The Aims are: (1) Investigate the in vivo
mechanisms by which NOD2 modulates neutrophil-mediated host defense during pneumonic sepsis; (2)
Explore the in vivo mechanisms by which NOD2 enhances IL-17A production during pneumonic sepsis;
and (3) Determine if modulation of NOD2 alters host defense during pneumonic sepsis. A unique
combination of in vivo and in vitro systems, including KO mice, overexpression and adoptive transfer
strategies will be employed to address these aims. We believe that this conceptually, technically and
translationally innovative proposal will reveal NOD2 as a master regulator for pneumonic sepsis and
advance our understanding of how NOD2 promotes a beneficial response for pneumonic sepsis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Innate Immunity in Pneumonic Sepsis
-
批准号:9755490
-
项目类别:
-
资助金额:$44.13万
-
财政年份:2016
-
负责人:Shanshan Cai
-
依托单位:
海外基金